viernes, 4 de junio de 2010


New trials of a daily polypill - combining aspirin, a statin and two blood pressure lowering medicines – are underway worldwide.

The hope is that this quartet of generics in the so-called “red heart pill” could save the lives of people who have had a heart attack or stroke, or are at risk.

Currently the difficulty is that such patients need multiple drugs to fulfill the same function - so a low-cost, once-daily combination could mean people are better at keeping up with their doses.

The UMPIRE (use of a multidrug pill in reducing cardiovascular events) trial will involve 1,000 patients in European at sites in London, Dublin and Utrecht, and – pending regulatory approval - another 1,000 subjects in India at approximately 30 sites.

The trial is based on two similar trials running concurrently. The Kanyini-GAP study in Australia and IMPACT (improving adherence using combination therapy) study in New Zealand, which will recruit both Maori and non-Maori people.

Like these studies, UMPIRE will evaluate whether the polypill - made by Dr Reddy's Laboratories - improves clinical outcomes among high-risk patients compared with usual medications.


Ver anteriores
Publicar un comentario